Content

Welcome to the CJU website » LOG IN

Details

Three year results of the prostatic urethral L.I.F.T. study
Roehrborn G. Claus; Rukstalis B. Daniel; Barkin Jack; Gange N. Steven; Shore D. Neal; Giddens L. Jonathan; Bolton M. Damien; Cowan E. Barrett; Cantwell L. Anthony; McVary T. Kevin; Te E. Alexis; Gholami S. Shahram; Moseley G. William; Chin T. Peter; Dowling T. William; Freedman J. Sheldon; Incze F. Peter; Coffield Scott K.; Borges D. Fernando; Rashid Prem; University of Texas Southwestern Medical Center, Dallas, Texas, USA
Jun 2015 (Vol. 22, Issue 3, Pages( 7772 - 7782)
PMID: 26068624

    Abstract

    Text-Size + 

  • INTRODUCTION: To report the three year results of a multi-center, randomized, patient and outcome assessor blinded trial of the Prostatic Urethral Lift (PUL) in men with bothersome lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: At 19 centers in North America and Australia, 206 subjects = 50 years old with International Prostate Symptom Score (IPSS) ≥ 13, peak flow rate (Qmax) ≤ 12 mL/s, and prostate volume between 30 cc-80 cc were randomized 2:1 to the PUL procedure or sham control. PUL involved placing permanent UroLift implants into the lateral lobes of the prostate to enlarge the urethral lumen. After randomized comparison at 3 months, PUL patients were followed to 3 years. LUTS severity (IPSS), quality of life, Qmax, sexual function, and adverse events were assessed throughout follow up. RESULTS: The therapeutic effect of PUL regarding IPSS was 88% greater than sham at 3 months. Average improvements from baseline through 3 years were significant for total IPSS (41.1%), quality of life (48.8%), Qmax (53.1%), and individual IPSS symptoms. Symptomatic improvement was independent of prostate size. There were no de novo, sustained ejaculatory or erectile dysfunction events and all sexual function assessments showed average stability or improvement after PUL. Fifteen of the 140 patients originally randomized to PUL required surgical reintervention for treatment failure within the first 3 years. CONCLUSIONS: PUL offers rapid improvement in voiding and storage symptoms, quality of life and flow rate that is durable to 3 years. Patients demonstrated a level of symptom relief that is associated with significant patient satisfaction. PUL, a minimally invasive procedure, is very effective in treating bothersome LUTS secondary to benign prostatic obstruction (BPO) and is unique in its ability to preserve total sexual function while offering a rapid return to normal physical activities.

Current Issue

Feb 2017, Vol.24 No.1
canadian journal of urology mobile

canadian journal of urology